141
Views
0
CrossRef citations to date
0
Altmetric
Patent Evaluation

Evaluation of WO2011045166A1, Fkbp52–tau interaction as a novel therapeutical target for treating the neurological disorders involving tau dysfunction

, , , &

Bibliography

  • Antero S, Johanna O, Kai K, et al. Hsp90 regulates tau pathology through co-chaperone complexes in Alzheimer’s disease. Prog Neurobiol 2011;93:99-110
  • Cheryl LS, Chad AD, Mario DG, et al. FKBP51 and FKBP52 in signaling and disease. Trends Endocrinol Metab 2011;22:481-90
  • Mi K, Johnson G. The role of tau phosphorylation in the pathogenesis of Alzheimer’s disease. Curr Alzheimer Res 2006;3:449-63
  • Mocanu MM, Nissen A, Eckermann K, et al. The potential for beta-structure in the repeat domain of tau protein determines aggregation, synaptic decay, neuronal loss. and coassembly with endogenous Tau in inducible mouse models of tauopathy.J Neurosci 2008;28:737-48
  • Steinhilb ML, Dias SD, Fulga TA, et al. Tau phosphorylation sites work in concert to promote neurotoxicity in vivo. Mol Biol Cell 2007;18:5060-8
  • Goedert M, Spillantini MG. Tau gene mutations and neurodegeneration. Biochem Soc Symp 2001;67:59-71
  • Chambraud B, Sardin E, Giustiniani J, et al. A role for FKBP52 in Tau protein function. Proc Natl Acad Sci USA 2010;107:2658-63
  • Gold BG. FK506 and the role of the immunophilin FKBP-52 in nerve regeneration. Drug Metab Rev 1999;31:649-63
  • Gold BG, Storm DT, Austin DR. The immunosuppressant FK506 increases functional recovery and nerve regeneration following peripheral nerve injury. Restor Neurol Neurosci 1994;6:287-96
  • Hamilton GS, Huang W, Connolly MA, et al. FKBP12-binding domain analogues of FK506 are potent, nonimmunosuppressive neurotrophic agents in vitro and promote recovery in a mouse model of parkinson’s disease. Bio Med Chem Lett 1997;7:1785-90
  • Lam E, Martin MM, Timerman AP, et al. A novel FK506 binding protein can mediate the immunosuppressive effects of FK506 and is associated with the cardiac ryanodine receptor. J Biol Chem 1995;270:26511-22
  • Ruan BF, Pong K, Jow F, et al. Binding of rapamycin analogs to calcium channels and FKBP52 contributes to their neuroprotective activities. Proc Natl Acad Sci USA 2007;105:33-8
  • Ittner LM, Gotz J. Amyloid-β and Tau--a toxic pas deux in Alzheimer’sdisease. Nat Rev Neurosci 2011;12:65-72
  • Liu F, Wang YQ, Meng L, et al. FK506-binding protein 12 ligands: a patent review. Expert Opin Ther Pat 2013;23:1435-49
  • Reeves C, Chu D, Khosla C, et al. Polynucleotides encoding the fkbA gene of the FK-520 polyketide synthase gene cluster. US6759536B2 2004
  • Sauer H, Francis JM, Jiang H, et al. Systemic treatment with GPI-1046 improves spatial memory and reverses cholinergic neuron atrophy in the medial septal nucleus of aged mice. Brain Res 1999;842:109-18
  • Steiner JP, Hamilton GS, Ross DT, et al. Neurotrophic immunophilinligands stimulate structural and functional recovery in neurodegenerative animal models. Proc Natl Acad Sci 1997;94:2019-24
  • Marshall V, Grosset D. GPI-1485 (Guilford). Curr Opin Investig Drugs 2004;5(1):107-12
  • Ninds NP. A randomized clinical trial of coenzyme Q10 and GPI-1485 in early Parkinson disease. Neurology 2007;68:20-8

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.